This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Bristol-Myers, Celgene face US antitrust claims over Pomalyst

( March 25, 2024, 22:31 GMT | Official Statement) -- MLex Summary: A New York welfare fund filed US antitrust claims accusing Bristol-Myers and Celgene of unlawfully extending a monopoly in the market for pomalidomide, a blockbuster drug used in the treatment of multiple myeloma and sold under the brand name Pomalyst. According to the complaint, Celgene engaged in a pattern of fraud on the US patent office, abused the federal judicial system, and shared some of its illicitly acquired profits with would-be generic competitors to have them further delay entering the market.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections